CRYOcheck™ Chromogenic Factor IX assay for the determination of factor IX activity in human plasma.

CRYOcheck™ Chromogenic Factor IX is a chromogenic assay for the determination of factor IX activity in human plasma. It is intended to be used as an aid in the management of hemophilia B in individuals aged two years or older. With a limit of quantification of 0.7% FIX activity and a test range of 0–200% FIX using one standard curve*, CRYOcheck Chromogenic Factor IX provides unsurpassed assurance in results, especially in cases of patients with severe hemophilia B. For in vitro diagnostic use.

Factor VIII is a critical component in the normal blood clot-forming process; upon activation of the coagulation cascade, it binds to factors IXa and X (FIXa and FX) to enable activation of FX and subsequent downstream thrombin activation, which leads to cleavage of fibrinogen and formation of a polymerized fibrin clot. Haemophilia A is an inherited bleeding disorder caused by a decrease or functional deficiency in factor VIII (FVIII), which leads to a lifelong bleeding tendency. The standard treatment for patients with haemophilia A without inhibitors is intravenous (IV) FVIII replacement therapy with recombinant FVIII (rFVIII) or plasma-derived FVIII (pdFVIII) concentrates. CRYOcheck Chromogenic Factor VIII is used for determination of FVIII activity. Unlike, clot-based FVIII activity tests, the chromogenic method offers the advantage of being less prone to interference from lipids or traces of heparin in samples.

CRYOcheck Chromogenic Factor VIII is a two-stage assay for use with automated coagulometers. In the first stage of the chromogenic assay, test plasma (containing an unknown amount of FVIII) is added to a reaction mixture comprised of calcium, phospholipids, purified human thrombin and FIXa, and FX of bovine origin. This mixture swiftly activates FVIII to FVIIIa, which works in concert with FIXa to activate FX. When the reaction is stopped, FXa production is assumed to be proportional to the amount of functional FVIII present in the sample. The second stage of the assay is to measure FXa through cleavage of a FXa-specific peptide nitroanilide substrate. The product (p-nitroaniline) produces a yellow colour that can be measured spectrophotometrically by absorbance at 405 nm. The colour produced is directly proportional to the amount of functional FVIII present in the sample based on a standard curve.